Skip to main content

Table 3 Associations between plasma sex hormones and serrated polyp in postmenopausal women from the NHSI and NHSII

From: Plasma sex hormones and risk of conventional and serrated precursors of colorectal cancer in postmenopausal women

Biomarker

Serrated polyp, OR (95% CI)a

Q1 (lowest)

Q2

Q3

Q4 (highest)

P for trend

Per 1-SDb

Estrone

 No. of cases

45

48

47

53

  

 Model 1

1

1.13 (0.74–1.71)

1.11 (0.73–1.69)

1.39 (0.92–2.11)

0.33

1.07 (0.93–1.23)

 Model 2

1

1.11 (0.72–1.69)

1.05 (0.69–1.61)

1.26 (0.79–1.99)

0.74

1.03 (0.88–1.21)

Total estradiol

 No. of cases

52

47

48

65

  

 Model 1

1

0.93 (0.62–1.39)

0.96 (0.64–1.43)

1.51 (1.04–2.19)

0.02

1.24 (1.04–1.47)

 Model 2

1

0.90 (0.59–1.35)

0.86 (0.57–1.30)

1.30 (0.85–1.99)

0.15

1.17 (0.95–1.44)

Free estradiol

 No. of cases

47

38

54

55

  

 Model 1

1

0.77 (0.50–1.19)

1.20 (0.81–1.80)

1.40 (0.94–2.10)

0.01

1.28 (1.07–1.52)

 Model 2

1

0.69 (0.44–1.08)

1.09 (0.72–1.65)

1.14 (0.70–1.86)

0.13

1.18 (0.95–1.46)

Total testosterone

 No. of cases

96

96

88

89

  

 Model 1

1

1.02 (0.76–1.36)

0.90 (0.67–1.21)

0.96 (0.71–1.29)

0.66

0.98 (0.88–1.09)

 Model 2

1

1.01 (0.76–1.36)

0.86 (0.64–1.16)

0.88 (0.65–1.20)

0.32

0.95 (0.85–1.05)

Free testosterone

 No. of cases

75

86

93

92

  

 Model 1

1

1.17 (0.85–1.60)

1.34 (0.99–1.83)

1.47 (1.08–2.01)

0.003

1.19 (1.06–1.34)

 Model 2

1

1.04 (0.76–1.43)

1.05 (0.76–1.45)

1.03 (0.73–1.44)

0.49

1.05 (0.92–1.19)

SHBG

 No. of cases

117

102

78

81

  

 Model 1

1

0.79 (0.60–1.04)

0.59 (0.44–0.79)

0.55 (0.41–0.73)

<.0001

0.79 (0.71–0.87)

 Model 2

1

0.89 (0.67–1.18)

0.70 (0.51–0.96)

0.72 (0.51–1.02)

0.01

0.86 (0.76–0.97)

Total estradiol/total testosterone

 No. of cases

48

45

46

59

  

 Model 1

1

0.91 (0.60–1.38)

0.95 (0.63–1.43)

1.35 (0.91–2.01)

0.08

1.16 (0.98–1.38)

 Model 2

1

0.86 (0.56–1.32)

0.86 (0.56–1.32)

1.23 (0.78–1.92)

0.24

1.13 (0.92–1.38)

  1. Abbreviations: NHS the Nurses’ Health Study, OR odds ratio, CI confidence interval, SHBG sex hormone-binding globulin, MET metabolic equivalent task, AHEI Alternative Healthy Eating Index
  2. aModel 1 was adjusted for age (continuous), case or control status, fasting status (yes or no), time period of endoscopy (in 2-year intervals), number of prior endoscopies (continuous), and time in years since the most recent endoscopy (continuous); model 2 was additionally adjusted for race (Caucasian or non-Caucasian), family history of colorectal cancer (yes or no), height (continuous), smoking status (never, ever, or current), AHEI score (quartile), body mass index (continuous), physical activity (< 3.0, 3.0–8.9, 9.0–17.9, 18.0–26.9, ≥ 27.0 MET-hours/week), alcohol consumption (0, 0.1–4.9, 5.0–9.9, 10.0–14.9, ≥ 15.0 g/day), regular aspirin use (yes or no), and postmenopausal hormone therapy (never, ever, or current)
  3. bSD was the standard deviation of log-transformed hormone levels: 0.58 for estrone, 0.79 for total estradiol, 0.84 for free estradiol, 0.50 for total testosterone, 0.64 for free testosterone, 0.62 for SHBG, and 0.80 for the ratio of total estradiol to total testosterone